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Abstract: Differential microRNA expression in colon adenocarcinoma (CA) was previously reported. MicroRNA biogenesis 
and function requires a set of proteins designated as the microRNA machinery, which includes DICER1 and PRKRA. Loss 
of heterozygosity at 14q32.13 DICER1 locus was detected in up to 60% of CA cases. The in silico gene array analysis of 
CA showed down-regulation of DICER1 and an up-regulation of PRKRA. Immunohistochemically, DICER1 expression 
was abnormal in 65% of CA (95 of 147 cases). PRKRA was deregulated in 70% of CA (32 of 46 cases). Expression of 
DICER1 and PRKRA was correlated with clinicopathologic features of CA. DICER1 up-regulation was seen more com-
monly in women. Only 10 of 46 cases immunostained for both DICER1 and PRKRA showed normal levels of both DICER1 
and PRKRA. Microsatellite status of 32 cases was determined. Microsatellite instable cases showed DICER1 up-regulation 
more commonly when compared to microsatellite stable cases; however, this trend was not statistically signiﬁ  cant. Abnor-
mal DICER1 and/or PRKRA expression might explain the observed changes in microRNA proﬁ  le. The status of the endog-
enous DICER1 and PRKRA in CA may help to predict the response to future RNA interference-based therapy.
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Introduction
MicroRNAs (miRs) are a class of small noncoding 21-nt long RNAs that have been implicated in the 
development of multiple types of human malignancies (Zhang, 2006), including colon adenocarcinoma 
(CA) (Bandres, 2006; Lanza, 2007; Michael, 2003; Volinia, 2006). Production and function of miR 
requires a set of proteins designated as the miR machinery (summarized in (Chiosea, 2006)). In the 
cytoplasm, DICER1 cuts both strands of the pre-miR duplex, generating a mature ~21-nucleotide miR 
duplex (Hutvagner, 2001). PRKRA (protein kinase, interferon-inducible double-stranded RNA-dependent 
activator) has been shown to interact with DICER1 without facilitating its pre-miRNA cleavage activity 
(Lee, 2006).
In a miR-guided fashion, the miR machinery regulates the expression of multiple tumor suppressor 
genes and oncogenes (Hammond, 2006). The list of miR with known cancer gene targets continues to 
grow (e.g. bcl-2, c-myc, RAS) (Calin and Croce, 2006). Independently of the RNAi pathway, DICER1 
controls checkpoints in response to mutagenic stress (Carmichael, 2004).
Mature miR-143 and miR-145 exhibit reduced levels in neoplastic colorectal tissue. This occurs in 
the background of constant levels of miR-143 and miR-145 precursors in both normal and tumor tissues 
(Michael, 2003). Recently, signiﬁ  cant differences were described in miRNA expression between mic-
rosatellite stable and microsatellite instable CA (Lanza, 2007). In part, this and other changes in miR 
expression could be due to altered levels of microRNA-associated proteins. For instance, the overall 
incidence of loss of heterozygosity at DICER1 locus is 60% in the distal colon and 28.6% in the 
proximal colon (Bando, 1999). Here, we present the in silico transcriptional analysis of DICER1 and 
PRKRA and further describe alterations of DICER1 and PRKRA expression in CA.
Material and Methods
Clinical proﬁ  le of cases and screening parafﬁ  n-embedded 
tissue microarray (TMA)
The demographic and clinicopathologic features of the patients in this study are listed in Table 1. 
TMAs were constructed using a semi-automatic tissue arrayer (Chemicon, San Diego, CA). 254
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Formalin-ﬁ  xed parafﬁ  n-embedded tumor blocks 
were selected and marked after microscopic 
examination of corresponding hematoxylin and 
eosin stained slides. One-millimeter cores were 
extracted from marked areas and arrayed in dupli-
cate onto two recipient blocks. To assess the 
potentially different DICER1 expression at the 
invasive front of cancer, whole sections of eight 
cases included in TMA and 20 additional cases 
were stained for DICER1.
Immunohistochemical stains 
and statistical analysis
Immunohistochemistry was performed as 
previously described (Chiosea, 2006). Brieﬂ  y, the 
slides were incubated at 4 °C overnight with anti-
DICER1 antibodies (Clonegene, Hartford, CT, 
1:400 dilution) and anti-PRKRA (Santa Cruz 
Biotechnology, Santa Cruz, CA, 1:800). The non-
neoplastic colonic mucosa epithelium adjacent to 
the areas of neoplasm served as an internal 
positive control. The intensity for the DICER1 
and PRKRA was graded semiquantitatively on a 
scale from 1 to 3. The staining was scored as “1” 
if the staining intensity in the neoplasm was lower 
than the staining intensity of the normal colonic 
epithelium. The staining was scored as “2” if the 
staining intensity in the neoplasm matched the 
staining intensity of the normal colonic epithelium. 
The staining was scored as “3” if the staining 
intensity in the neoplasms exceeded the staining 
intensity of the normal colonic. Two pathologists 
(R.S. and S.C.) scored the stained slides. The ﬁ  nal 
score assigned to the case was the average of the 
two cores rounded up to the nearest numeric 
category. For instance, when the average score 
after analyzing 2 or more cores from one case was 
1.5 it was counted as less than 2, i.e. a score of 
“1” was assigned. Statistical analysis was 
performed with SPSS 14.0 software (SPSS Inc, 
Chicago, IL). Two group comparisons were 
performed with the Fisher exact test with 
a p-value of  0.05 considered statistically 
signiﬁ  cant.
Microsatellite status
was determined as previously described (Trusky, 
2006). To select cases for microsatellite status 
evaluation modiﬁ  ed Bethesda criteria were applied 
to consecutive cases of CA (outlined in (Gologan, 
2005)). Shortly, under direct visualization using a 
stereomicroscope normal tissue and tumor targets 
from 6 unstained sequential blank slides at 5 μm 
thick and radius of at least 6 mm were microdis-
sected. Dissection was performed according to the 
marked H and E slides. The tumor targets are 
selected for  90% tumor cells. Areas of stroma 
and necrosis were avoided. The samples were 
treated with proteinase K (New England Biolabs, 
Ipswich, MA) overnight at 60 °C and then DNA 
was extracted using the Qiagen DNEasy kit 
(Qiagen, Valencia, CA) according to manufacture’s 
recommendations. DNA concentration was 
obtained for each sample by using a spectropho-
tometer (Nanodrop Technologies, Wilmington, 
DE). The 260/280 ratio was calculated to conﬁ  rm 
purity in the samples. PCR was then performed 
using 1 mL of puriﬁ  ed DNA and ﬂ  uorescently 
labeled primers designed for the 5 standard NCI-
recommended microsatellite repeat loci (BAT25, 
BAT26, D2S123, D5S346, and D17S250), 2 mono-
nucleotides, and 3 dinucleotides (Boland, 1998). 
PCR products were semiquantitatively analyzed 
using the ABI Prism 3100 and Genescan software 
(Applied Biosystems, Foster City, CA). Interpreta-
tion was performed as previously described 
(Trusky, 2006).
Table 1. Clinicopathologic and demographic charac-
terization of the patients.
Mean age, years (range)  68 (24 to 93)
 50 129
 50 18
Gender Male  61
            Female  86
Normal colon tissue  11
Colorectal carcinoma  147
Laterality Right  79
       Left  68
T stage 
  In  situ  1
  T1  13
  T2  24
  T3  101
  T4  8
Lymph node status, N0  74
Lymph node status, N1 (1–3)  40
Lymph node status, N2 ( 4) 30
Known distant metastasis  19
MSS 15
MSI (HNPCC)  13 (5)
Cases with both cores missing on all examined TMA sections were 
excluded from the analysis. Nodal status is unknown in 3 cases. 
MSS, microsatellite stable; MSI, microsatellite instable.255
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Results
In Silico analysis of expression array 
data reveals deregulation of DICER1 
and PRKRA in CA
Using Oncomine, a newly developed, Internet-
based query tool (www.Oncomine.org) (Rhodes, 
2004), we were able to query 5 previously pub-
lished expression array datasets of CA for DICER1 
and PRKRA. These data althouth publicly available 
for analysis through Oncomine, were never pre-
sented before. All studies had signiﬁ  cance level of 
P   0.05. The DICER1 expression was altered in 
2 of 5 studies. DICER1 was down regulated in CA 
compared to normal colon (Table 2 and Fig. 1A). 
Also, lower DICER1 level was seen in CA with 
K-ras mutation when compared to wild type 
K-ras (Table 3 and Fig. 1A) (Koinuma, 2006; 
Zou, 2002).
Equal PRKRA expression characterizes nor-
mal colon tissue and CA (Table 2). However, CA 
at advanced stages showed higher PRKRA level 
than earlier stages of CA (−0.4 normalized 
expression units in Duke Stage A vs. 0.8 in Duke 
Stage D) (Table 2 and Fig. 1C. PRKRA was 
up-regulated in CA with wild type BRAF 
(Table 3)(Koinuma, 2006).
Changes of other miR machinery genes are 
summarized in Tables 2 and 3.
Immunohistochemical analysis of 
DICER1 and PRKRA expression in CA
DICER1 and PRKRA expression in normal colon 
was limited to mucosal epithelium (Fig. 2). Both 
proteins showed similar cytoplasmic expression. 
One hundred forty seven cases of CA were stained 
for DICER1. DICER1 expression was abnormal 
in 65% (95 of 147) tumors. Fifty-four cases of CA 
showed up-regulation, 43 CA showed down-
regulation and 52 cases had normal immunoreac-
tivity for DICER1. DICER1 was more commonly 
down-regulated among women (p = 0.05). In whole 
sections, there was minor regional heterogeneity 
but no predilection for tumoral regions (i.e. surface 
component, etc. invasive front).
Forty-one cases were stained for PRKRA, also. 
PRKRA was deregulated in CA in 70% (32 of 46 
cases). PRKRA level was increased in 43% of CA 
(20 of 46 cases) and decreased in 26% of CA (12 
of 46 cases). Expression of DICER1 and PRKRA 
is summarized in Table 4. Expression of DICER1 
or PRKRA did not correlate with TNM staging 
parameters, independently or by stage group, lat-
erality, and age. Only 10 cases showed normal 
levels of both DICER1 and PRKRA.
To address the question of DICER1 expression 
and mismatch repair system we analyzed DICER1 
expression in 15 cases of mcirosatellite stable 
(MSS) CA and 18 cases of microsatellite instable 
(MSI) CA (including 5 cases of hereditary nonpol-
yposis colorectal carcinoma syndrome, HNPCC). 
Most MSI cases showed DICER1 up-regulation 
(10 of 18 cases); however, this trend is not statisti-
cally signiﬁ  cant when compared to MSS cases. 
Normal DICER1 immunoreactivity was seen in 5 
of 18 MSI cases.
Discussion
Differential miR expression in CA was shown by 
several independent studies (Bandres, 2006; 
Michael, 2003; Volinia, 2006). The suggested set 
Table 2. MicroRNA machinery changes and colon cancer progression: a summary of gene array studies.
MicroRNA machinery-associated genes, median, normalized expression units
DICER1 0.5 −0.7                
EIF2C2  −0.4  0.6  0.2  0.02  0.08  0.3         
PRKRA     −0.4  −0.3  −0.3  0.8         
HSP90          −0.2 0.2  −0.4 0.2 −0.2 0.3
EIF2C1     0.4  0.45  0.4  0.3         
SND1          −0.25 0.13 −0.3 0.2 −0.4 0.3
Sample,    N CA  A  B  C  D  N  CA  N CA N CA
n  8  9  6  14 14 6  12  18  22 40 18 18
Study  (Zou,   (Koinuma, 2006)  (Graudens,  (Alon,   (Notterman,
 2002)    2006)  1999)  2001)
Abbreviations: n: number of samples; N: normal colonic mucosa; A, B, C, and D: Duke stages; CA: colon adenocarcinoma.256
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of miRs differentiating normal from cancer tissues 
is composed of 18 miRNA, 10 down-regulated and 
8 up-regulated (Bandres, 2006). In a recent analy-
sis of 23 microsatellite stabile (MSS), CA and 16 
CA with microsatellite instability (MSI), 8 microR-
NAs were up-regulated and, along with 15 mRNA, 
could correctly distinguish MSI versus MSS CA 
samples (Lanza, 2007).
Little is known about the mechanisms of miR 
regulation in normal and neoplastic tissues. In a 
non-cancer type speciﬁ  c study, miR genes were 
found to be commonly located at minimal regions 
of ampliﬁ  cation, loss of heterozygosity, and break-
point regions suggesting that abnormal miR pro-
ﬁ  les can be caused by somatic genetic mutation 
(Zhang, 2006). However, in colon tumors miR 
expression did not correlate with the miR gene 
copy numbers (Lamy, 2006).
New details about the transcriptional and post-
transcriptional regulation of miR expression have 
been discovered: deacetylation of chromatin pro-
teins was thought to be an important factor capable 
to alter global miR levels (Scott, 2006).
More importantly, tissue-speciﬁ  c miR process-
ing can be regulated by DICER1 (Obernosterer, 
2006). Mature miR-143 and miR-145 are reduced 
in neoplastic colon tissue, while unprocessed pre-
cursors of these miRs remain at a constant level 
(Michael, 2003). This result suggests that transcrip-
tional changes are not accountable for reduced miR 
levels. More likely reduction in miRs is secondary 
to the decrease in DICER1-processing activity. 
Intuitively, reduced DICER1 activity should result 
in more generalized effect on miR expression. 
However, in adenocarcinoma cell lines displaying 
hypomorphic DICER1 phenotype, of 97 known 
Table 3. MicroRNA machinery genes change with BRAF, K-ras mutations and Microsatellite Instability (MSI) 
status of CA.
MicroRNA machinery-associated gene, median, normalized expression units
DICER1        0.05  −0.3
EIF2C2 0.4  −0.1 0.4  −0.05  
PRKRA 0.6  −0.4      
TNRC6B  −0.18 0.17 −0.11 0.16  0.02  −0.27
SND1  0.3  −0.5 0.4  −0.5  −0.02 0.15
DDX20     −0.08 0.1   
Sample, n  WT   Mutant   MSI   MSI   K-Ras  Mutant
  BRAF,   BRAF,   Neg,   Pos,  WT,   K-Ras,
  22 18 20  20  32  8
Study (Koinuma,  2006)
Figure 1. Oncomine meta-analysis of CA expression arrays for miR machinery-associated genes. The box plot is the interquartile range and 
the whiskers are the 10–90th% range. Normalized expression units are log2 transformed. Array Median is set to 0 and array standard 
deviation is set to 1. A. DICER1 was signiﬁ  cantly down-regulated in CA samples (n = 9) when compared to normal colonic mucosa samples 
(n = 8). DICER1 was down-regulated in CA specimens positive for K-Ras mutation (n = 8) when compared to K-Ras wild type samples 
(n = 32). B. Ago2 was signiﬁ  cantly up-regulated in CA. C. CA at an advanced stage (Duke D, n = 6) showed higher PRKRA level than earlier 
stages of CA (Duke A, n = 6; Duke B, n = 14, and Duke C, n = 16).
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miRs, only 55 were differentially expressed 
(Cummins, 2006). This observation suggests that 
DICER1 is required for the biogenesis of only a 
subset of known miRs (Cummins, 2006).
One of ﬁ  ve gene array studies in presented 
in silico gene array analysis of CA showed lower 
DICER1 level in 9 analyzed CA when compared 
to normal colon mucosa (Rhodes, 2004; Zou, 
2002). We demonstrate that in increased number 
of specimens an almost equal proportion of CA 
demonstrates loss or decrease of DICER1 expres-
sion. Our results show no correlation between level 
of DICER1 expression and CA progression. This 
result is in agreement with the work by Koinuma 
et al. (Koinuma, 2006). PRKRA increase in 
advanced CA stages shown in the same study is 
probably quantitatively too minor to be translated 
into a signiﬁ  cant change at PRKRA protein level 
(Koinuma, 2006). The gene expression data and 
the protein expression values are derived from 
different samples and could show conﬂ  icting fea-
tures. However, our samples as well as the samples 
in Koinuma et al. (2006) are not believed to rep-
resent special groups or subtypes of colon tumors, 
and general features should thus be conserved 
between the specimens. A limitation of this study 
is the lack of knowledge on BRAF and K-Ras status 
of cases analyzed for DICER1immunoreactivity.
It has been shown that the overall incidence of 
LOH at 14q32 DICER1 locus (D14S267 marker) 
in the distal large bowel (60%, 21/35) tended to be 
signiﬁ  cantly higher than that in the proximal bowel 
(28.6%, 4/14) (Bando, 1999). Our more extended 
study did not show correlation between DICER1 
expression and the site of CA.
We have previously demonstrated the role of 
DICER1 in the development of prostate adenocar-
cinoma (Chiosea, 2006) and non-small cell lung 
carcinoma (Chiosea, 2007). DICER1 expression 
varies in squamous cell carcinoma of the esophagus 
and does not show signiﬁ  cant association with 
patient survival (Sugito, 2006). Together with 
DICER1 and PRKRA changes in CA described 
here, alterations of microRNA machienry might 
be a new common theme of carcinogenesis.
Interestingly, we found decreased expression of 
DICER1 in colon tumors from females. miR 
machinery may be one of probably several bio-
markers differentially expressed across gender. 
One epidemiologic study suggests that women 
present with more aggressive disease when con-
trolled for age, race and anatomic subsite (Woods, 
2005). However, the review of the Surveillance, 
Epidemiology, and End Results Program database 
yielded the opposite results (Wingo, 1998). The 
contributory role of miR machinery to gender dif-
ference has to be validated in a large study.
There is an increasing evidence that potential 
RNA interference based therapy can have non-
speciﬁ  c effects, including off-target silencing and 
activation of the interferon system (Jackson and 
Linsley, 2004). Furthermore, as was shown by 
Grimm et al., shRNA expression in hepatocytes 
following intravenous infusion can result in fatal 
dose-dependent liver tissue injury. Adverse effects 
were most likely caused by competition of exog-
enous siRNA pathway with the endogenous miR 
pathway, for instance Exportin-5 (Grimm, 2006). 
The widespread changes of DICER1 and PRKRA 
Figure 2. DICER1 immunoreactivity in normal colon mucosa and CA. A. Normal colonic mucosa. DICER1 immunoreactivity is limited to the 
basal rim of cytoplasm. B. A representative example of CA with loss of DICER1. C. A representative example of CA with increased diffuse 
cytoplasmic DICER1 expression. Immunohistochemistry, ×200 original magniﬁ  cation.
Table 4. Expression of both DICER1 and PRKRA in CA, 
number of cases.
PRKRA/DICER1 Up  N  Down
Up 9  6  5
N 2  5  7
Down 2  4  6258
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expression in CA described here, might not only 
explain some abnormalities in the miR proﬁ  le of 
CA, but also may help to predict the response to 
future RNAi-based therapy.
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